Home    Back

Neurovax    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica4

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 3,050 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02200718
(ClinicalTrials.gov)		December 31, 202017/7/2014A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple SclerosisA Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple SclerosisMultiple SclerosisBiological: NeuroVax;Biological: IFA Incomplete Freund's AdjuvantImmune Response BioPharma, Inc.NULLNot yet recruiting5 Years17 YearsAll12Phase 1United States
2NCT02057159
(ClinicalTrials.gov)		March 9, 20204/2/2014A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple SclerosisA Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple SclerosisSecondary Progress Multiple Sclerosis;Multiple SclerosisBiological: NeuroVax;Biological: IFA PlaceboImmune Response BioPharma, Inc.croRecruiting18 Years50 YearsAll200Phase 2;Phase 3United States
3NCT02149706
(ClinicalTrials.gov)		March 9, 202024/5/2014A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple SclerosisA Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via VaccinationMultiple SclerosisBiological: NeuroVax;Biological: IFA Incomplete Freund's AdjuvantImmune Response BioPharma, Inc.croNot yet recruiting18 Years70 YearsAll150Phase 2United States
4EUCTR2006-003384-30-SK
(EUCTR)		26/02/200708/11/2006A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple SclerosisA Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis Multiple SclerosisProduct Name: NeuroVax 300ug/mL Dose for IM Injection
Product Code: IR902
Other descriptive name: VB6S5
Other descriptive name: VB13S1
Other descriptive name: VB5S2		The Immune Response CorporationNULLNot RecruitingFemale: yes
Male: yes		200Phase 2Slovakia